Allspring Global Investments
CLYM

Allspring Global Investments’s Climb Bio CLYM Stock Holding History

Allspring Global Investments’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,400
Closed -$20K – 2970
2022
Q1 		$20K Sell
2,400
-480
-17% -$4.48K ﹤0.01% 2942
2021
Q4 		$30K Buy
+2,880
New +$42.9K ﹤0.01% 2884

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PL
Parkwood LLC Cleveland, Ohio $1.13B AUM 32.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Allspring Global Investments's CLYM Position: Q2 2022 in Review

Allspring Global Investments sold out of Climb Bio (CLYM) in Q2 2022, closing a stake of 2,400 shares — an estimated $20K sold.

Allspring Global Investments first reported a position in CLYM in Q4 2021 and held it in 2 quarters. The position peaked at $30K in Q4 2021. 29 funds tracked by Wall St. Rank hold CLYM as of Q2 2022.

  • Allspring Global Investments reported no remaining Climb Bio position as of Q2 2022 after selling out during the quarter.
  • Allspring Global Investments sold 2,400 Climb Bio shares in Q2 2022, an estimated $20K.
  • Allspring Global Investments first reported a position in Climb Bio in Q4 2021 and held it in 2 quarters.
  • Allspring Global Investments's Climb Bio position peaked at $30K in Q4 2021.
  • 29 funds tracked by Wall St. Rank held Climb Bio as of Q2 2022.

Based on Allspring Global Investments's 13F filing for Q2 2022, filed 25 Jul 2022.